company background image
HIK

Hikma Pharmaceuticals LSE:HIK Stock Report

Last Price

UK£15.27

Market Cap

UK£3.4b

7D

-1.0%

1Y

-31.9%

Updated

08 Dec, 2022

Data

Company Financials +
HIK fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance2/6
Financial Health4/6
Dividends5/6

HIK Stock Overview

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products.

Hikma Pharmaceuticals PLC Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hikma Pharmaceuticals
Historical stock prices
Current Share PriceUK£15.27
52 Week HighUK£22.77
52 Week LowUK£11.75
Beta0.27
1 Month Change16.26%
3 Month Change18.75%
1 Year Change-31.88%
3 Year Change-20.83%
5 Year Change41.34%
Change since IPO441.31%

Recent News & Updates

Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Sep 27
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Recent updates

Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Sep 27
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price

Jun 24
Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price

These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well

Jun 06
These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well

Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly

Feb 26
Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly

Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price

Dec 01
Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price

Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?

Nov 11
Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?

Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?

Sep 02
Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?

Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Aug 09
Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate

May 21
Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate

Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly

May 03
Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly

It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year

Apr 16
It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year

How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?

Apr 13
How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?

Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend

Mar 14
Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend

Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Feb 28
Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

I Ran A Stock Scan For Earnings Growth And Hikma Pharmaceuticals (LON:HIK) Passed With Ease

Feb 22
I Ran A Stock Scan For Earnings Growth And Hikma Pharmaceuticals (LON:HIK) Passed With Ease

Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 23% Undervaluation?

Feb 03
Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 23% Undervaluation?

Are Hikma Pharmaceuticals's (LON:HIK) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Jan 20
Are Hikma Pharmaceuticals's (LON:HIK) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Hikma Pharmaceuticals PLC (LON:HIK) Vies For A Place In Your Dividend Portfolio: Here's Why

Jan 08
Hikma Pharmaceuticals PLC (LON:HIK) Vies For A Place In Your Dividend Portfolio: Here's Why

How Much Of Hikma Pharmaceuticals PLC (LON:HIK) Do Institutions Own?

Dec 25
How Much Of Hikma Pharmaceuticals PLC (LON:HIK) Do Institutions Own?

What Did Hikma Pharmaceuticals' (LON:HIK) CEO Take Home Last Year?

Dec 14
What Did Hikma Pharmaceuticals' (LON:HIK) CEO Take Home Last Year?

If You Had Bought Hikma Pharmaceuticals (LON:HIK) Shares Three Years Ago You'd Have Earned 167% Returns

Dec 04
If You Had Bought Hikma Pharmaceuticals (LON:HIK) Shares Three Years Ago You'd Have Earned 167% Returns

Hikma Pharmaceuticals PLC's (LON:HIK) Stock Is Going Strong: Is the Market Following Fundamentals?

Nov 23
Hikma Pharmaceuticals PLC's (LON:HIK) Stock Is Going Strong: Is the Market Following Fundamentals?

A Look At The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Jul 23
A Look At The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Does Hikma Pharmaceuticals (LON:HIK) Deserve A Spot On Your Watchlist?

Jul 08
Does Hikma Pharmaceuticals (LON:HIK) Deserve A Spot On Your Watchlist?

Shareholder Returns

HIKGB PharmaceuticalsGB Market
7D-1.0%1.9%-1.3%
1Y-31.9%8.0%-9.3%

Return vs Industry: HIK underperformed the UK Pharmaceuticals industry which returned 8.4% over the past year.

Return vs Market: HIK underperformed the UK Market which returned -9.2% over the past year.

Price Volatility

Is HIK's price volatile compared to industry and market?
HIK volatility
HIK Average Weekly Movement5.4%
Pharmaceuticals Industry Average Movement5.4%
Market Average Movement5.8%
10% most volatile stocks in GB Market10.7%
10% least volatile stocks in GB Market2.9%

Stable Share Price: HIK is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: HIK's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19788,700Said Samih Darwazahhttps://www.hikma.com

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded.

Hikma Pharmaceuticals PLC Fundamentals Summary

How do Hikma Pharmaceuticals's earnings and revenue compare to its market cap?
HIK fundamental statistics
Market CapUK£3.36b
Earnings (TTM)UK£283.09m
Revenue (TTM)UK£2.09b

11.9x

P/E Ratio

1.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HIK income statement (TTM)
RevenueUS$2.55b
Cost of RevenueUS$1.24b
Gross ProfitUS$1.31b
Other ExpensesUS$962.00m
EarningsUS$346.00m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Feb 23, 2023

Earnings per share (EPS)1.57
Gross Margin51.29%
Net Profit Margin13.57%
Debt/Equity Ratio67.0%

How did HIK perform over the long term?

See historical performance and comparison

Dividends

2.9%

Current Dividend Yield

36%

Payout Ratio